Cinclus Pharma Holding AB (publ) (STO:CINPHA)
Sweden · Delayed Price · Currency is SEK 12.62
+0.20 (1.61%)
At close: Sep 4, 2026
Cinclus Pharma Holding AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 387.92 | 487.25 | 566.72 | 87.97 | 173.55 | 138.2 |
Cash & Short-Term Investments | 387.92 | 487.25 | 566.72 | 87.97 | 173.55 | 138.2 |
Cash Growth | -34.13% | -14.02% | 544.20% | -49.31% | 25.57% | -33.72% |
Accounts Receivable | - | 16.06 | 4.58 | - | - | - |
Other Receivables | 4.41 | 5.9 | 2.93 | 3.98 | 10.23 | 1.38 |
Receivables | 4.41 | 21.96 | 7.51 | 3.98 | 10.23 | 1.38 |
Prepaid Expenses | 24.24 | 2.2 | 1.23 | 2.14 | 1.11 | 0.39 |
Other Current Assets | - | 25.44 | 25.02 | - | - | 5.38 |
Total Current Assets | 416.57 | 536.85 | 600.47 | 94.09 | 184.88 | 145.36 |
Property, Plant & Equipment | 7.68 | 9.41 | 0.54 | 0.32 | 0.89 | 1.82 |
Other Long-Term Assets | 0.3 | 0.3 | 0 | 0 | 0 | 0 |
Total Assets | 424.54 | 546.56 | 601.01 | 94.41 | 185.77 | 147.18 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 41.4 | 48.46 | 18.93 | 16.45 | 16.95 | 9.19 |
Accrued Expenses | 20.69 | 20.83 | 16.9 | 6.83 | 20.47 | 7.51 |
Short-Term Debt | 48.31 | - | - | 131.01 | - | - |
Current Portion of Leases | 3.24 | 3.11 | 0.11 | 0.02 | 0.54 | 0.85 |
Current Income Taxes Payable | - | 0.21 | 7.45 | 7.22 | 5.4 | - |
Current Unearned Revenue | 48.93 | 54.53 | - | - | - | - |
Other Current Liabilities | 18.44 | 9.66 | 2.11 | 2.9 | 2.74 | 1.92 |
Total Current Liabilities | 181.02 | 136.79 | 45.49 | 164.42 | 46.1 | 19.47 |
Long-Term Leases | 3.13 | 4.79 | 0.19 | - | - | 0.61 |
Long-Term Unearned Revenue | 37.7 | 35.59 | - | - | - | - |
Other Long-Term Liabilities | 0 | -0 | - | 6.79 | 12.8 | - |
Total Liabilities | 221.84 | 177.17 | 45.68 | 171.21 | 58.9 | 20.08 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.92 | 0.92 | 0.92 | 0.51 | 0.51 | 0.26 |
Additional Paid-In Capital | 1,298 | 1,298 | 1,298 | 503.52 | 503.69 | 276.74 |
Retained Earnings | -1,120 | -952.8 | -772 | -606.84 | -394.16 | -145.08 |
Comprehensive Income & Other | 23.8 | 23.53 | 28.67 | 26 | 16.84 | -4.82 |
Shareholders' Equity | 202.7 | 369.39 | 555.33 | -76.8 | 126.87 | 127.1 |
Total Liabilities & Equity | 424.54 | 546.56 | 601.01 | 94.41 | 185.77 | 147.18 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 54.68 | 7.9 | 0.3 | 131.03 | 0.54 | 1.46 |
Net Cash (Debt) | 333.24 | 479.36 | 566.42 | -43.06 | 173 | 136.75 |
Net Cash Growth | -43.40% | -15.37% | - | - | 26.51% | -34.41% |
Net Cash Per Share | 6.50 | 10.29 | 15.29 | -1.64 | 7.51 | 6.48 |
Filing Date Shares Outstanding | 46.54 | 46.54 | 46.54 | 26.23 | 0.33 | 0.26 |
Total Common Shares Outstanding | 46.54 | 46.54 | 46.54 | 26.23 | 0.33 | 0.26 |
Working Capital | 235.55 | 400.06 | 554.97 | -70.33 | 138.78 | 125.89 |
Book Value Per Share | 4.36 | 7.94 | 11.93 | -2.93 | 387.00 | 481.30 |
Tangible Book Value | 202.7 | 369.39 | 555.33 | -76.8 | 126.87 | 127.1 |
Tangible Book Value Per Share | 4.36 | 7.94 | 11.93 | -2.93 | 387.00 | 481.30 |